Note: Although this FDA-483 is an
accurate representation of the original FDA-483 issued to the firm, it is not an exact
copy. Slight modifications to the original FDA-483 have been made to accommodate its
conversion to the HTML format. A scanned copy of the original FDA-483 is available in PDF format on
this website. |
DEPARTMENT OF
HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION |
DISTRICT OFFICE ADDRESS AND PHONE NUMBER
6000 Metro Drive, Suite 101
Baltimore, Maryland 21215 |
DATE(S) OF INSPECTION:4/22 - 12/20/02 |
FEI NUMBER:1000123507 |
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED
TO:Ramesh Thadani, Executive Vice President and
Chief Executive Officer |
FIRM
NAME
American National Red Cross/Biomedical Services |
STREET
ADDRESS
1616 Fort Myer Drive |
CITY,
STATE AND ZIP CODE
Arlington, Virginia 22209 |
TYPE OF
ESTABLISHMENT INSPECTED
National Headquarters of a Licensed Blood Bank |
changed and their initials had been forged in the changed documents. The report
indicates one employee stated He was afraid of losing his job and he knew if he
brought a complaint up to the top, he would have been found out and then set up to be
fired.
- ARC uses a system known as the Hotline as another means in which an employee
can report concerns or problems related to the manufacturing of blood products, donor and
patient safety as well as human resource matters. The following hotline
records describe reports from ARC employees of allegations of significant record keeping
irregularities:
ARC #[REDACTED]: The records of investigation provided by ARC indicate
one employee was terminated for falsification of records on 5/31/02 and a
second employee was forced to resign due to falsification of records
backdated records.
ARC #[REDACTED]: The records of investigation provided by ARC indicate
the employee reported that a cooler was allowed to go 12 degrees above temperature but it
was never documented. The cooler was re-cooled and then reported at the proper
temperature.
ARC [REDACTED]: The records of investigation provided by ARC indicate the
issues investigated were: caller states nurses are using out of date test tubes and
falsifying documents; caller suggests falsification of documents should be
ground for termination; and caller states acting supervisor instructs
employees to falsify documents in order to hide mistakes.
ARC #[REDACTED]: The records of investigation provided by ARC indicate
the caller stated the team manager completed a donors Blood Donation Record
(BDR) by placing the confidential unit exclusion form on the BDR for the donor.
ARC #[REDACTED]: The records of investigation provided by ARC indicate an
employee was instructed to alter the donors history to indicate the initial pulse
rate to be 98 beats per minute instead of 104 beats per minute. The records also
state it was determined that you instructed other staff members on the blood drive
to keep this to themselves and not allow this deviation to surface.
ARC #[REDACTED]: The records of investigation provided by ARC indicate an
employee reported that management at an apheresis center has the employees continue with
the collections even though the machine alarms indicate a donors platelet count is
too low to continue or complete the donation. It was also reported that employees are told
not to document this alarm type in the alarm log.
ARC #[REDACTED]: The records of investigation provided by ARC indicate a
supervisor changed the information on training records because he failed to properly
release a new employee to perform Anti-HBc testing at an NTL. The record also states
caller stated
falsified documentation in the red book and the trainee roster
which he/she stated is a violation of FDA regulations.
|
SEE REVERSE OF THIS PAGE |
EMPLOYEE(S) SIGNATURE
[Handwritten] Initials: MTC, LSM, SJW |
EMPLOYEE(S)
NAME AND TITLE [Handwritten]
Mary T. Carden, Investigator
Linda S. Mattingly, Investigator
Stephany J. Wesley, Investigator |
DATE ISSUED
12/20/02 |
FORM FDA 483 (8/00) PREVIOUS EDITION OBSOLETE INSPECTIONAL
OBSERVATIONS
Reverse Text on Page: The observations of objectional conditions and practices listed
on the front of this form are reported:
- Pursuant to Section 704(b) of the Federal Food, Drug and
Cosmetic Act, or
- To assist firms inspected in complying with the Acts and
regulations enforced by the Food and Drug Administration.
|
Section 704(b) of the Federal Food, Drug, and Cosmetic
Act (21 USC374(b)) provides: "Upon
completion of any such inspection of a factory, warehouse, consulting laboratory, or other
establishment, and prior to leaving the premises, the officer or employee making the
inspection shall give to the owner, operator, or agent in charge a report in writing
setting forth any conditions or practices observed by him which, in his judgement,
indicate that any food, drug, device, cosmetic in such establishment (1) consists in whole
or in part of any filthy, putrid, or decomposed substance or (2) has been prepared,
packed, or held under insanitary conditions whereby it may have become contaminated with
filth, or whereby it may have been rendered injurious to health. A copy of such report
shall be sent promptly to the Secretary." |
Web page created by ORA Web Team 12/20/2002
|